US DISTRICT COURT FINDS SEROQUEL XR® FORMULATION PATENT VALID AND INFRINGED
2012-03-30 AstraZeneca today announced that the US District Court for the District of New Jersey has found the formulation patent protecting SEROQUEL XR® (quetiapine fumarate) extended release tablets to be valid. The court also ruled that Anchen Pharmaceuticals, Inc., Osmotica Pharmaceutical Corporation, Torrent Pharmaceuticals Limited, Torrent Pharma Inc., Mylan Pharmaceuticals Inc. and Mylan Inc. have infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017. This follows a decision made in the UK on 22 March 2012, which found the formulation
